Bruton Tyrosine Kinase (BTK) inhibitors find application in the therapeutic management of B-cell disorders, such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström macroglobulinemia, and marginal zone lymphoma. Here, BTK is linked to Waldenstrom macroglobulinemia.